ECOG 1A05: Randomized Phase III Trial of Consolidation Therapy with Bortezomib (Velcade) –Lenalidomide (Revlimid) –Dexamethasone (VRD) versus Bortezomib (Velcade) –Dexamethasone (VD) for Patients With Multiple Myeloma who have completed a Dexamethasone Based Induction Regimen.

Trial Profile

ECOG 1A05: Randomized Phase III Trial of Consolidation Therapy with Bortezomib (Velcade) –Lenalidomide (Revlimid) –Dexamethasone (VRD) versus Bortezomib (Velcade) –Dexamethasone (VD) for Patients With Multiple Myeloma who have completed a Dexamethasone Based Induction Regimen.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 30 Jun 2015

At a glance

  • Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Jun 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 01 Jul 2013 Planned end date changed from 1 Apr 2013 to 1 Aug 2013 as reported by ClinicalTrials.gov.
    • 11 Jul 2012 Planned end date changed from 1 Aug 2009 to 1 Apr 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top